Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share

v3.8.0.1
Earnings (Loss) Per Common Share
6 Months Ended
Dec. 31, 2017
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]
10.
Earnings (Loss) Per Common Share
 
Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):
 
 
 
Three Months ended
December 31,
 
Six Months ended
December 31,
 
 
 
2017
 
2016
 
2017
 
2016
 
Basic and diluted numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to iBio, Inc.
 
$
(3,899)
 
$
(3,229)
 
$
(7,725)
 
$
(6,290)
 
Preferred stock dividends
 
 
65
 
 
-
 
 
131
 
 
-
 
Net loss available to iBio, Inc. stockholders
 
$
(3,964)
 
$
(3,229)
 
$
(7,856)
 
$
(6,290)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic and diluted denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted-average common shares outstanding
 
 
96,609
 
 
89,109
 
 
96,127
 
 
89,109
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Per share amount
 
$
(0.04)
 
$
(0.04)
 
$
(0.08)
 
$
(0.07)
 
 
In Fiscal 2018 and Fiscal 2017, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share are the same. As of December 31, 2017 and 2016, shares issuable which could potentially dilute future earnings included approximately 13.6 million and 12.3 million stock options, respectively.